Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.

@article{Wals2007VaccinatingAA,
  title={Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.},
  author={P De Wals and Laurent Coudeville and Pierre Trottier and Catherine Chevat and Lonny James Erickson and Van Hung Nguyen},
  journal={Vaccine},
  year={2007},
  volume={25 29},
  pages={5433-40}
}
BACKGROUND One dose of serogroup C meningococcal conjugate vaccine (MCV-C) at 12 months of age is the most common immunization schedule in Canada, but immunity may wane over time. OBJECTIVES To assess the cost-effectiveness of a booster dose at 12 years of age with either MCV-C or a quadrivalent ACYW135 meningococcal conjugate vaccine (MCV-4). METHODS A simulation model for assessing both the direct and indirect effects of vaccination was developed. Age- and serogroup-specific incidence and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…